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Abstract
Therapeutic response to selective serotonin (5-HT) reuptake inhibitors in Major Depressive Disorder (MDD) varies
considerably among patients, and the onset of antidepressant therapeutic action is delayed until after 2 to 4 weeks of
treatment. The objective of this study was to analyze changes within methoxyindole and kynurenine (KYN) branches of
tryptophan pathway to determine whether differential regulation within these branches may contribute to mechanism of
variation in response to treatment. Metabolomics approach was used to characterize early biochemical changes in
tryptophan pathway and correlated biochemical changes with treatment outcome. Outpatients with MDD were randomly
assigned to sertraline (n = 35) or placebo (n = 40) in a double-blind 4-week trial; response to treatment was measured using
the 17-item Hamilton Rating Scale for Depression (HAMD17). Targeted electrochemistry based metabolomic platform
(LCECA) was used to profile serum samples from MDD patients. The response rate was slightly higher for sertraline than for
placebo (21/35 [60%] vs. 20/40 [50%], respectively, x2(1) = 0.75, p = 0.39). Patients showing a good response to sertraline
had higher pretreatment levels of 5-methoxytryptamine (5-MTPM), greater reduction in 5-MTPM levels after treatment, an
increase in 5-Methoxytryptophol (5-MTPOL) and Melatonin (MEL) levels, and decreases in the (KYN)/MEL and 3-
Hydroxykynurenine (3-OHKY)/MEL ratios post-treatment compared to pretreatment. These changes were not seen in the
patients showing poor response to sertraline. In the placebo group, more favorable treatment outcome was associated with
increases in 5-MTPOL and MEL levels and significant decreases in the KYN/MEL and 3-OHKY/MEL; changes in 5-MTPM levels
were not associated with the 4-week response. These results suggest that recovery from a depressed state due to treatment
with drug or with placebo could be associated with preferential utilization of serotonin for production of melatonin and 5-
MTPOL.
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Introduction
Selective serotonin (5-HT) reuptake inhibitors (SSRIs) are the
most commonly prescribed antidepressant medications for the
treatment of Major Depressive Disorder (MDD). The primary
target for SSRIs is the 5-HT transporter, inhibition of the
transporter initiates multiple changes within different branches of
the tryptophan pathway; yet antidepressant effects are very
complex, and several pathways have been implicated in their
mechanism of action, in addition to affecting serotoninergic
neurotransmission, SSRIs also influence other systems, such as
dopamine [1–3] and norepinephrine [4–6], as well as glutamate
[7–9] and c-aminobutyric acid [10–12].
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Response to current therapies in treating MDD varies
considerably, and onset of antidepressant therapeutic action
typically does not occur until after 2 to 4 weeks of treatment
which delays clinicians from knowing whether an antidepressant is
going to work for a particular patient [13],[14]. Mechanisms
underlying the variation in the likelihood and timing of treatment
response in depression remain largely unknown, different mech-
anisms are likely involved due to the multiple effects of
antidepressants and the heterogeneity of the disease [15–22].
The placebo effect adds even more complexity; the mechanisms
underlying the placebo response may differ from those involved in
the response to SSRIs, thus making it more difficult to identify
mechanisms involved in the therapeutic action of the medication
[23–25]. Placebo response could also reflect spontaneous im-
provement and thus change in placebo group that corresponds to
improvement in depression could reflect disease state alterations
independent of medication.
Metabolomics tools enable identification and quantification of
hundreds to thousands of compounds that can report on changes
in biochemical pathways [26]. Recently, we started to apply
metabolomics approaches to map global biochemical changes in
depression and pathways implicated in mechanism of variation of
response to SSRIs [27–29]. Recently we found that metabolic
profiles in MDD patients prior to treatment could distinguish
responders from non-responders to sertraline or placebo; several
tryptophan pathway metabolites contributed to the separation of
responders and non-responders in that study [30]. In the present
study we provide detailed mapping of effects of sertraline and
placebo on key neurotransmitter pathways after one week and four
weeks of treatment and correlate biochemical changes with
treatment outcomes. A detailed analysis of changes within
methoxyindole and kynurenine (KYN) branches of tryptophan
pathway is conducted based on findings that differential regulation
within these branches may contribute to mechanism of variation in
response to treatment. The metabotype of a depressed patient at
baseline and the biochemical changes induced by treatment can
inform about treatment outcomes and can highlight heterogeneity
in a complex disease such as depression.
Materials and Methods
Study Design
The 75 patients in this report were a subset of the 165 patients
who entered a randomized, double-blind, flexible dosing, placebo-
controlled study performed at 12 clinical sites. Sertraline dosing
was started at 50 mg/day at baseline (week 0), with dose increased
up to 100 mg/day at week 1 and up to 150 mg/day at week 2, as
seen needed by the treating clinician. Subjects selected for this
study were those with serum samples and HAMD17 scores
available at baseline and 1 week and at 4 weeks (+/21 week)
after treatment. Finally, the subset of participants in this study
largely overlaps with those used in our previous study [30].
Patients and Samples
Study participants were outpatients, 18–65 years of age, from
various clinical sites across the United States. Patients had a
primary diagnosis of nonpsychotic MDD by the criteria specified
in the Diagnostic and Statistical Manual of Mental Disorders, 4th
Edition, with symptoms of depression present for at least one
month prior to screening, and a total baseline score .22 on the
17-item HAMD17 at screening. A complete description of the
inclusion and exclusion used in this study can be found in
Table S1. The study protocol was developed in accordance with
the principles of the Declaration of Helsinki. All patients provided
written informed consent. The study was sponsored and moni-
tored by Pfizer, Inc. Each site’s institutional review board
approved and oversaw the study. The primary outcome measure
was the HAMD17, used to assess depressive symptom severity.
Measures were gathered at baseline, and weeks 1 and 4 of
treatment at the patient’s visits. Serum samples were collected
using standard protocol at baseline, week 1 and week 4 of
treatment at the clinic visits. Whole blood was collected in serum
collection tubes and inverted 5–8 times. Serum samples were
allowed to clot at room temperature for 60 minutes and then
centrifuged at 1,3006g for 15 minutes. Following centrifugation
supernatant was frozen at 280uC until analysis.
Metabolomic Profiling
Samples were analyzed using a liquid chromatography electro-
chemical array (LCECA) platform that has been extensively
validated and used in our prior studies in neurodegenerative and
psychiatric disorders [30–34]. The method includes multiple
compounds from the tyrosine, tryptophan, sulfur amino acids and
purine pathways, and markers of oxidative stress and protection
(for the list of metabolites and abbreviations see Table 1). Levels of
5-Methoxytryptamine (5-MTPM) were measured using a gas
chromatography time-of-flight-mass spectrometry (GCTOF-MS)
platform [29]. Samples were prepared for analysis as previously
described [30]. During the sample preparation, pools were created
from equal volumes of subaliquots of all samples. Concentrations
of metabolites in the individual samples were expressed as a
percentage of the concentration of those metabolites in the
averaged pool.
Statistical Methods
Data preprocessing: We first removed the metabolites that have
more than 40% missing values. Data from one subject who had
more than 50% metabolite data missing was excluded from
analysis. Most metabolites have right-skewed distribution; log
transformation was thus applied to the metabolite concentrations
at all three time points to induce normality of the data. Principal
components analysis (PCA; SIMCA-P+12.0) was used to identify
outliers. The analysis was performed for each time point. All
metabolites were first standardized to have mean 0 and standard
deviation 1. Subjects with $3 standard deviations away from the
center of data cloud within two principal components (PC’s) scores
scatter plot were considered outliers and were removed from
further analysis.
Metabolic signatures of sertraline and placebo. Paired t-
tests were used to examine which metabolites changed significantly
from baseline to week 1 and from baseline to week 4. These
analyses were conducted separately for the sertraline and placebo
groups. Between groups t-tests were used to compare baseline to
one week and baseline to four week change scores between the
sertraline and placebo groups.
Correlation analysis. Pearson correlation analysis was used
to examine associations of changes in metabolite levels with
concurrent change in depressive symptoms. Analyses were
conducted separately for one and four week change. Correlations
of the sertraline group and placebo group were compared using
the two-sample Z-test after hyperbolic tangent transformation.
Metabolic signatures in good and poor responders to
sertraline and placebo. Signatures of response to sertraline
and placebo were identified by using paired t-tests to compare
week 4 metabolite levels to baseline metabolite levels in the
responders and non-responders to therapy. Participants were
considered responders if they showed a $50% percent reduction
in HAMD17 scores after four weeks of treatment. These analyses
Methoxyindole Pathway Role in MDD
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were also performed to evaluate changes in ratios of individual
metabolites within (e.g., 5-HT/5-HTP) and between branches of
tryptophan pathway (e.g., KYN/MEL).
Correlation analysis of tryptophan pathway metabolites.
Pearson correlation analysis was used to examine associations of
the pre-treatment levels of tryptophan pathway metabolites and
ratios to the percent change in HAMD17 scores after four weeks of
treatment.
For all the above systematic univariate tests, q-values [35] were
calculated for controlling multiple testing false discovery rate.
Results
Sample Characteristics
The sertraline and placebo groups did not differ significantly in
age (44611.3 years vs. 40612.9 years, p = 0.15), gender (24/35
[69%] vs. 28/40 [70%] female, p = 0.89) or race (26/35 [74%] vs.
31/40 [78%] white, p = 0.75). The response rate was slightly
higher for sertraline than for placebo, but this difference was not
statistically significant (21/35 [60%] vs. 20/40 [50%] responders,
x2(1) = 0.75, p = 0.39). Age, gender, or race were not associated
with percent change in HAMD17 scores in either sertraline or
placebo group (Table S2). Due to potential diurnal variation in
levels of methoxyindoles we also analyzed whether there are
differences in blood collection times between sertraline and
placebo groups for both responders and non-responders. No
significant differences were found (data not shown).
Metabolic Signatures of Sertraline and Placebo – One
Week and Four Weeks Exposure
Metabolic signatures of sertraline after one and four
weeks of treatment. Several metabolites changed significantly
from baseline to week one in the group receiving sertraline
(Table 2). The most significant changes were decreased levels of 5-
HT and its major metabolite 5-HIAA. Other metabolites
significantly changed following the first week of treatment with
sertraline were from the purine and tyrosine/phenylalanine
pathways (Table 2). Several metabolites also showed significant
changes after four weeks of sertraline administration (Table 3).
Similar to one week, the most prominent change in this group was
the decrease in 5-HT levels. A number of other metabolites
showed significant increases including 4-HPLA, DIOHMAL,
tocopherols, 4-HPAC, METH, HGA, TYR, TRP, and MEL.
Compounds that changed after one week and four weeks of
treatment with sertraline are shown within their respective
pathways in Figure 1 A-C.
Metabolic signatures of placebo after one and four weeks
of treatment. Among the patients receiving placebo, a number
of metabolites showed significant changes from baseline to the first
week of treatment (Table 2); these included metabolites from the
purine, tyrosine, and tryptophan pathways, as well as tocopherols.
Several metabolites changed significantly from baseline to four
weeks in the placebo group (Table 3). These included significant
increases in 4-HPLA, HGA, tocopherols, 3-OHKY, TYR, and
METH. Compounds changed after one week and four weeks of
treatment with placebo are shown within their respective pathways
in Figure 1 A–C.
Metabolic signatures of sertraline vs. placebo. A com-
parison of the treatment signatures of sertraline and placebo
revealed some interesting patterns (Tables 2 and 3). Many
metabolites changes found in the sertraline group were also found
in the placebo group, including significant increases in 4-HPLA
and HGA after one week of treatment, and increases in 4-HPLA,
tocopherols, METH, TYR and HGA after four weeks of
treatment. The analysis of differential change yielded a significant
effect for 5-HT at one and four weeks. Whereas 5-HT levels
decreased in placebo group during the first week, the patients
taking sertraline had a greater reduction in serotonin over this time
period. Serotonin levels continued to decrease from week 1 to
week 4 among the patients taking sertraline. At four weeks 5-HT
levels in the placebo group were similar to those at baseline.
Metabolic changes in responders and non-responders are
presented in Tables S3 and S4.
Table 1. Metabolites Quantified by the LCECA platform.
Pathway Metabolite Abbreviation
Tryptophan 3-Hydroxykynurenine 3-OHKY
5-Hydroxyindoleacetic Acid 5-HIAA
5-Hydroxytryptophan 5-HTP
N-Acetylserotonin NA-5-HT
Anthranillic Acid ANA
Indole-3-lactic Acid I-3-LA
Melatonin MEL
Serotonin 5-HT
Tryptophan TRP
5-Methoxytryptophol 5-MTPOL
Tryptophol TRPOL
Kynurenine KYN
Tyrosine 3-O-methyldopa 3-OMD
4-Hydroxyphenylacetic Acid 4-HPAC
3,4-Dihydroxyphenylacetic Acid DOPAC
3,4-Dihydroxymandelic Acid DIOHMAL
Homogentistic Acid HGA
Homovanillic Acid HVA
L-DOPA LD
Methoxyhydroxyphenlyglycol MHPG
Tyrosine TYR
Vanillylmandelic Acid VMA
Phenylalanine 4-Hydroxybenzoic Acid 4-HBAC
4-Hydroxyphenyllactic Acid 4-HPLA
Purine 7-Methylxanthine 7-MXAN
Guanosine GR
Guanosine Mono Phosphate GRMP
Hypoxanthine HX
Uric Acid UA
Xanthine XAN
Xanthosine XANTH
Cysteine, Glutathione Glutathione (reduced) GSH
Cysteine CYS
Antioxidants Delta-Tocopherol DTOCO
Alpha-Tocopherol ATOCO
One Carbon Metabolism Methionine METH
Other Vanillic Acid VANA
doi:10.1371/journal.pone.0068283.t001
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Figure 1. Changes in metabolites within (A) tryptophan, (B) tyrosine and (C) purine metabolism pathways. Abbreviations: HIOMT =
hydroxyindole-O-methyltransferase; 5-HIAD = 5-Hydroxyindole acetyldehyde; NM-5-HT = N-methyl serotonin; 5-HTPOL = 5-Hydroxytryptophol;
5-MIAA =5-Methoxyindole acetic acid; 5-MTPM =5-methoxytryptamine. For the remaining metabolites, see Table 1.
doi:10.1371/journal.pone.0068283.g001
Methoxyindole Pathway Role in MDD
PLOS ONE | www.plosone.org 4 July 2013 | Volume 8 | Issue 7 | e68283
Associations of Change in Metabolites with Treatment
Outcome
We also examined associations between metabolite changes and
treatment outcome. Following one week of sertraline treatment,
changes in 5-HT and KYN were associated with symptoms
reduction from baseline (r =20.38, p = 0.017 for 5-HT; r = 0.32,
p = 0.047 for KYN). For placebo group, changes in DOPAC levels
correlated with the treatment response (r =20.51 and
p = 0.00059). A direct comparison of one-week correlations
between the two groups, however, did not reveal any significant
differences.
After four weeks of treatment, changes in metabolites from
tryptophan pathway correlated with the percent change in
HAMD17 scores in the placebo group, including 5-MTPOL,
MEL and 5-HIAA (r = 0.34, p = 0.028; r = 0.32, p = 0.036 and
r =20.31, p = 0.040, respectively). Following four weeks of
treatment changes in 4-HPAC had different (p = 0.042) correla-
tions with outcome between sertraline (r = 0.27) and placebo
(r =20.20) groups.
Table 2. Metabolic changes after one week treatment with sertraline and placebo.
Compound Pathway Sertraline Placebo Comparison
Change P-value Q-value Change P-value Q-value P-value Q-value
TRPOL Tryptophan 0.033 0.74 0.64 20.21 0.016 0.062 0.062 0.8
5-HT Tryptophan 20.75 2.8E-12 2.4E-10 20.21 0.014 0.062 4.7E-06 5.5E-04
5-HIAA Tryptophan 20.17 0.00041 0.011 20.036 0.40 0.45 0.031 0.67
5-HTP Tryptophan 20.11 0.21 0.34 20.019 0.84 0.63 0.49 0.91
5-MTPOL Tryptophan 0.041 0.50 0.52 0.016 0.81 0.62 0.78 0.94
5-MTPM Tryptophan 21.8 0.075 0.22 22.2 0.031 0.090 0.31 0.91
KYN Tryptophan 20.045 0.23 0.35 0.043 0.21 0.29 0.084 0.80
NA-5-HT Tryptophan 0.0079 0.90 0.71 0.06 0.35 0.41 0.56 0.91
TRP Tryptophan 0.0036 0.92 0.71 0.063 0.067 0.14 0.23 0.86
3-OHKY Tryptophan 20.074 0.20 0.34 0.096 0.087 0.16 0.035 0.67
MEL Tryptophan 0.34 0.10 0.23 0.3 0.22 0.30 0.89 0.97
LD Tyrosine 0.081 0.37 0.43 20.22 0.043 0.11 0.032 0.67
HVA Tyrosine 0.053 0.46 0.48 0.019 0.8 0.62 0.74 0.94
VMA Tyrosine 0.11 0.029 0.13 0.041 0.41 0.45 0.31 0.91
DOPAC Tyrosine 20.13 0.22 0.34 0.051 0.67 0.59 0.26 0.86
MHPG Tyrosine 20.17 0.33 0.42 0.051 0.82 0.62 0.43 0.91
TYR Tyrosine 0.083 0.10 0.23 0.11 0.024 0.073 0.68 0.92
3-OMD Tyrosine 20.12 0.16 0.30 0.14 0.17 0.26 0.05 0.73
4-HPAC Tyrosine 0.29 0.0044 0.057 0.15 0.072 0.15 0.26 0.86
DIOHMAL Tyrosine 0.18 0.091 0.23 0.25 0.0057 0.032 0.59 0.91
HGA Tyrosine 0.28 0.015 0.10 0.27 2.5E-05 0.0019 0.93 0.97
XAN Purine 20.19 0.029 0.13 20.25 0.00017 0.0045 0.56 0.91
HX Purine 20.07 0.38 0.44 20.22 0.0043 0.032 0.17 0.86
GR Purine 20.23 0.31 0.40 20.13 0.56 0.56 0.76 0.94
7-MXAN Purine 20.099 0.74 0.64 20.1 0.72 0.59 0.99 0.98
GRMP Purine 20.011 0.90 0.71 20.033 0.69 0.59 0.85 0.97
XANTH Purine 0.082 0.16 0.30 20.022 0.62 0.59 0.15 0.86
UA Purine 20.077 0.0061 0.057 0.011 0.71 0.59 0.032 0.67
METH
One Carbon
Metabolism
0.097 0.084 0.23 0.14 0.056 0.13 0.64 0.91
4-HPLA Phenylalanine 0.1 0.0049 0.057 0.095 0.0044 0.032 0.83 0.97
4-HBAC Phenylalanine 20.085 0.77 0.65 0.19 0.46 0.49 0.48 0.91
ATOCO Antioxidant 0.21 0.29 0.40 0.48 0.0048 0.032 0.27 0.86
DTOCO Antioxidant 0.3 0.30 0.40 0.5 0.039 0.10 0.60 0.91
CYS Cysteine, Glutathione 20.034 0.21 0.34 0.039 0.25 0.32 0.089 0.8
GSH Cysteine, Glutathione 20.013 0.44 0.47 20.0067 0.72 0.59 0.81 0.96
Changes in absolute concentrations of metabolites (log-transformed) after one week are shown; positive values – up-regulated metabolites, negative values– down-
regulated metabolites. Significant changes are shown in bold. See methods section for the details of statistical analysis. Abbreviations: 5-MTPM – 5-methoxytryptamine;
for the remaining metabolites, see Table 1.
doi:10.1371/journal.pone.0068283.t002
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Analysis of Tryptophan Pathway and Treatment Outcome
Analysis of metabolic changes that correlates with treatment
outcome suggests that different branches within tryptophan
metabolism might be regulated differently in responders and
non-responders to drug and to placebo. Therefore we performed
more targeted and comprehensive analysis of the tryptophan
pathway, with a focus on the methoxyindole and KYN branches in
responders and non-responders to sertraline and placebo
(Figure 2). Correlations between baseline levels of individual
metabolites, as well as the ratios of individual metabolites within
and among branches of tryptophan pathway, and four weeks
treatment outcome were evaluated. The ratios between levels of
individual metabolites could provide insights about enzymes that
are regulated differently in responders and non-responders. The
ratios of metabolites across branches of tryptophan metabolism
could provide insights about a shift in utilization of substrates for
different branches of tryptophan pathway.
Table 3. Metabolic changes after four week treatment with sertraline and placebo.
Compound Pathway Sertraline Placebo Comparison
Change P-value Q-value Change P-value Q-value P-value Q-value
TRPOL Tryptophan 0.061 0.5 0.49 20.015 0.88 0.46 0.57 0.92
5-HT Tryptophan 21.9 8.70E-12 7.10E-10 20.018 0.78 0.45 5.40E-12 6.40E-10
5-HIAA Tryptophan 20.06 0.31 0.36 0.015 0.79 0.45 0.36 0.91
5-HTP Tryptophan 0.12 0.1 0.16 0.0022 0.98 0.5 0.28 0.91
5-MTPOL Tryptophan 0.13 0.089 0.14 0.092 0.19 0.21 0.68 0.99
5-MTPM Tryptophan 20.29 0.0089 0.026 20.058 0.43 0.36 0.09 0.9
KYN Tryptophan 0.045 0.16 0.22 0.04 0.26 0.26 0.92 1
NA-5-HT Tryptophan 0.041 0.45 0.45 0.019 0.74 0.45 0.78 1
TRP Tryptophan 0.07 0.042 0.08 0.052 0.091 0.16 0.68 0.99
3-OHKY Tryptophan 0.044 0.41 0.42 0.11 0.045 0.1 0.4 0.91
MEL Tryptophan 0.49 0.044 0.08 0.17 0.5 0.38 0.37 0.91
LD Tyrosine 0.12 0.19 0.24 0.042 0.67 0.43 0.55 0.92
HVA Tyrosine 0.1 0.18 0.23 0.021 0.81 0.45 0.47 0.91
VMA Tyrosine 20.015 0.79 0.62 20.0078 0.88 0.46 0.92 1
DOPAC Tyrosine 20.014 0.9 0.67 0.12 0.21 0.22 0.37 0.91
MHPG Tyrosine 20.21 0.34 0.37 0.11 0.56 0.39 0.27 0.91
TYR Tyrosine 0.13 0.039 0.08 0.095 0.047 0.1 0.67 0.99
3-OMD Tyrosine 0.079 0.4 0.42 0.13 0.27 0.26 0.75 1
4-HPAC Tyrosine 0.26 0.0023 0.014 0.13 0.13 0.17 0.27 0.91
DIOHMAL Tyrosine 0.37 0.00091 0.0074 0.16 0.054 0.11 0.11 0.91
HGA Tyrosine 0.4 0.0062 0.022 0.3 0.0099 0.058 0.55 0.92
XAN Purine 20.16 0.042 0.08 20.11 0.086 0.15 0.56 0.92
HX Purine 20.0057 0.95 0.69 0.011 0.87 0.46 0.88 1
GR Purine 0.0002 1 0.7 20.18 0.51 0.38 0.63 0.99
7-MXAN Purine 0.083 0.78 0.62 0.051 0.82 0.45 0.93 1
GRMP Purine 0.052 0.62 0.54 20.16 0.096 0.16 0.13 0.91
XANTH Purine 0.047 0.35 0.38 0.0063 0.88 0.46 0.54 0.92
UA Purine 20.058 0.056 0.095 20.015 0.66 0.43 0.34 0.91
METH
One Carbon Meta
bolism
0.2 0.0057 0.022 0.13 0.048 0.1 0.48 0.91
4-HPLA Phenylalanine 0.13 0.00024 0.0032 0.12 8.3E-4 0.012 0.85 1
4-HBAC Phenylalanine 0.12 0.69 0.59 0.13 0.7 0.45 0.99 1
ATOCO Antioxidant 0.63 0.0014 0.01 0.35 0.027 0.078 0.24 0.91
DTOCO Antioxidant 0.71 0.0037 0.017 0.4 0.019 0.063 0.27 0.91
CYS Cysteine, Glutathione 20.0014 0.97 0.69 20.044 0.27 0.26 0.42 0.91
GSH Cysteine, Glutathione 0.014 0.75 0.62 20.013 0.74 0.45 0.65 0.99
Changes in absolute concentrations of metabolites (log-transformed) after four week are shown; positive values – up-regulated metabolites, negative values– down-
regulated metabolites. Significant changes are shown in bold. See methods section for the details of statistical analysis. Abbreviations: 5-MTPM 25-methoxytryptamine;
for the remaining metabolites, see Table 1.
doi:10.1371/journal.pone.0068283.t003
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Tryptophan Pathway Analysis and Response to Sertraline
Correlations of pre-treatment metabolite levels and ratios of
metabolites to four week percent change in HAMD17 scores in the
sertraline treatment condition are presented in Figure 2A and
Tables 4 and 5. There was a significant positive correlation
between pre-treatment 5-MTPM levels and treatment response
indicating that higher levels of baseline 5-MTPM were associated
with a more favorable 4 week response. None of the other
correlations were significant. The ratios of 5-HIAA, NA-5-HT,
and MEL to both 5-HT and 5-MTPM tend to be lower in those
who responded to treatment. In general, the magnitude of the
correlations was greater for the ratios of 5-MTPM to the
metabolites of the other branches indicating that responders in
the sertraline group are characterized by greater activity in the 5-
MTPM branch relative to the other branch of tryptophan
pathway.
Binary analysis was used to examine changes in metabolites in
responders and non-responders in the four week sertraline group
(Figure 2C). There was a significant decrease in 5-MTPM levels in
good responders which is consistent with the correlation analysis.
At four weeks, responders to sertraline showed significant increases
Figure 2. Metabolites within methoxyindole branch of tryptophan pathway correlated with treatment response. Panels A and B show
correlations of metabolites at baseline with the four week treatment response in the sertraline and placebo groups, respectively. The correlations are
color coded as indicated by the color bar. Panels C and D show four week metabolic changes unique to responders in the sertraline and placebo
groups respectively. Abbreviations: HIOMT = hydroxyindole-O-methyltransferase; 5-HIAD = 5-Hydroxyindole acetyldehyde; NM-5-HT = N-methyl
serotonin; 5-HTPOL = 5-Hydroxytryptophol; 5-MIAA = 5-Methoxyindole acetic acid; 5-MTPM =5-methoxytryptamine. For the remaining metabolites,
see Table 1.
doi:10.1371/journal.pone.0068283.g002
Table 4. Correlations of pre-treatment levels of metabolites
within the tryptophan pathway to four-week percent change
in HAMD17 scores in Sertraline group.
Metabolites Correlation p-value q-value
5-MTPM 0.41 0.013 0.15
5-HT 0.29 0.093 0.35
5-MTPOL 20.24 0.16 0.35
NA-5-HT 20.24 0.17 0.35
MEL 20.22 0.20 0.35
5-HIAA 20.19 0.28 0.36
5-HTP 0.077 0.66 0.40
TRP 0.051 0.77 0.42
Note: A positive correlation coefficient indicates that higher concentrations of
metabolites are associated with a better four-week response of depression
status.
Abbreviations: 5-MTPM = 5-methoxytryptamine. For the remaining metabolites,
see Table 1.
doi:10.1371/journal.pone.0068283.t004
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in 5-MTPOL and MEL and a significant decrease in 5-HT. 5-HT
levels were also significantly reduced over the four week period in
the non-responders; however, 5-MTPOL, MEL, and 5-MTPM
levels were not significantly changed in this group. These latter
findings suggest that changes in MEL and 5-MTPOL levels could
play a role in the mechanisms of response to sertraline.
Analysis of ratios of metabolites between the kynurenine and
methoxyindole branches of tryptophan pathway revealed pro-
found differences between responders and non-responders to
sertraline (Table 6). Responders to sertraline showed significant
decreases in the KYN/MEL and 3-OHKY/MEL ratios from pre-
to post-treatment. This suggests that there is a shift in the relative
activity from the KYN branch of tryptophan pathway towards
melatonin production. The KYN/5-HT ratio also showed a
significant increase, but this increase was similar in responders and
non-responders. This likely reflects the marked decrease in
serotonin seen in both groups.
Tryptophan Pathway Analysis and Response to Placebo
Similarly to sertraline, we examined associations of tryptophan
pathway metabolites and ratios of metabolites to HAMD17
changes in the patients treated with placebo. The results of these
analyses are summarized in Figure 2B and Tables 7 and 8. There
was a significant negative correlation between baseline 5-MTPOL
and the change in HAMD17 scores indicating that lower pre-
treatment 5-MTPOL levels were associated with a better four
week outcome. The strongest ratio correlations with outcome were
for 5-MTPOL/TRP, 5-MTPM/5-MTPOL, 5-MTPM/5-HT,
and 5-MTPOL/5-HTP, although only the first one reached a
conventional level of significance.
Analyses of change in responders and non-responders to
placebo revealed that there were significant four week increases
in 5-MTPOL and MEL in responders to placebo (Figure 2D), a
pattern that was similar to that seen in the good responders in the
sertraline treatment condition. However, 5-MTPM was not
significantly changed in good responders to placebo. There were
no significant changes observed in the group of poor responders to
placebo. There were also significant pre- to post-treatment
decreases in the KYN/MEL and 3-OHKY/MEL ratios among
good responders to placebo (Table 9). As with sertraline, good
responders to placebo show a shift in tryptophan metabolism from
KYN production towards the production of MEL.
Tyrosine Pathway and Treatment Outcome. Correlating
pre-treatment metabolite levels to the four-week treatment
outcome did not yield any metabolites within the tyrosine pathway
that significantly correlate with response to treatment with drug or
placebo. An examination of changes in metabolites in responders
and non-responders in the sertraline group yielded 4-HPAC and
DIOHMAL to be significantly increased in responders (Ta-
ble S4A). DIOHMAL levels were also significantly increased over
the four week period in the non-responders (Table S4B).
Significant increases in LD and HGA levels after four weeks were
evident in the group showing poor response to sertraline
(Table S4B). In the placebo group HGA was increased in non-
responders and none of the other metabolites on the tyrosine
pathway were significantly changed in this treatment group
(Table S4B).
Discussion
The results of our recent metabolomics study indicated that
pretreatment serum metabolic signatures of MDD patients
allowed prediction of response to sertraline [30]. The current
Table 5. Correlations of pre-treatment levels of ratios of
metabolites within the tryptophan pathway to four week
percent change in HAMD17 scores in Sertraline group.
Ratios Correlation p-value
5-HTP/TRP 0.072 0.68
5-HT/TRP 0.19 0.28
NA-5-HT/TRP 20.28 0.10
5-HIAA/TRP 20.11 0.54
5-MTPOL/TRP 20.2 0.25
MEL/TRP 20.26 0.14
5-MTPM/TRP 0.32 0.058
5-HT/5-HTP 0.15 0.40
NA-5-HT/5-HTP 20.21 0.23
5-HIAA/5-HTP 20.17 0.34
5-MTPOL/5-HTP 20.21 0.24
MEL/5-HTP 20.31 0.068
5-MTPM/5-HTP 0.22 0.19
NA-5-HT/5-HT 20.33 0.051
5-HIAA/5-HT 20.33 0.054
5-MTPOL/5-HT 20.25 0.14
MEL/5-HT 20.38 0.024
5MTPM/5-HT 0.11 0.53
MEL/NA-5-HT 20.2 0.26
MEL/5MTPM 20.4 0.016
NA-5-HT/5MTPM 20.54 0.0007
5-HIAA/5MTPM 20.43 0.011
5-MTPOL/5MTPM 20.28 0.11
Note: A positive correlation coefficient indicates that responders favor higher
ratios.
Abbreviations: 5-MTPM = 5-methoxytryptamine. For the remaining metabolites,
see Table 1.
doi:10.1371/journal.pone.0068283.t005
Table 6. Change in tryptophan pathway ratios in responders
and nonresponders to sertraline.
Ratio Responder Nonresponder
Estimate p-value Estimate p-value
KYN/TRP 20.006 0.75 20.017 0.40
KYN/5-HTP 0.0057 0.88 20.076 0.11
KYN/5-HT 0.95 2.1E-10 0.72 0.00019
KYN/NA-5-HT 20.019 0.48 0.027 0.55
KYN/MEL 20.28 0.031 20.085 0.59
KYN/5-MTPOL 20.062 0.090 20.012 0.86
3-OHKY/TRP 0.013 0.67 20.04 0.20
3-OHKY/5-HTP 0.025 0.62 20.099 0.022
3-OHKY/5-HT 0.97 1.2E-09 0.69 0.00022
3-OHKY/NA-5-HT 20.00032 0.99 0.0038 0.94
3-OHKY/MEL 20.27 0.040 20.11 0.49
3-OHKY/5-MTPOL 20.043 0.21 20.035 0.67
Abbreviations: For the metabolites, see Table 1.
doi:10.1371/journal.pone.0068283.t006
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study extends on these findings by: (1) identifying the biochemical
changes that occur in MDD patients one week and four weeks
after treatment with sertraline or placebo; (2) identifying which
changes are associated with a reduction in depressive symptoms
after one and four weeks of treatment with sertraline or placebo.
In the sertraline group, we found a marked decrease in level of 5-
HT from baseline to both one and four weeks of the study, which is
significantly larger than that in the placebo group. This observation
is consistent with previous reports on the effects of SSRIs on blood
5-HT levels and most likely reflects inhibition of 5-HT transporter
and decreased levels of 5-HT in the platelets following chronic SSRI
treatment [2],[36]. Similar to the previous findings on fluoxetine
[2], no correlation between effects of sertraline on blood 5-HT levels
and early outcome of the treatment was found. Decreased 5-HT
levels were also observed at week one in the patients receiving
placebo; whether this early decrease is related to the disease itself or
reflects potential effect of placebo needs further investigation with
longer observation times and the inclusion of the drug/placebo-
naı¨ve patients and healthy control subjects.
In addition to decreased 5-HT and 5-HIAA levels, we observed
changes in other metabolites within the tryptophan pathway, both
at baseline and after treatment, and these effects were different for
responders and non-responders. There was a significant and
positive correlation between baseline 5-MTPM levels and
treatment response at four weeks, indicating that higher levels of
5-MTPM before treatment were associated with a more favorable
response. Levels of 5-MTPM were significantly reduced over the
four week treatment period, but only among good responders to
sertraline. Additionally, significant differences in the ratios
between several metabolites within the tryptophan pathway were
observed. The ratios of 5-HIAA, NA-5-HT and MEL to both 5-
HT and 5-MTPM were significantly lower in responders to
sertraline, compared to non-responders. In the responders to
sertraline levels of 5-MTPOL and MEL were significantly
increased over the four week treatment period, while in the non-
responders levels of 5-MTPOL, MEL and 5-MT were not
affected. Neither KYN nor the other metabolites within the
kynurenine branch of tryptophan pathway were significantly
altered in the group receiving sertraline. Analysis of the ratios
showed an increase in KYN/5-HT and 3-OHKY/5-HT ratios
following four week treatment both in responders and
Table 7. Correlations of pre-treatment levels of metabolites
within the tryptophan pathway to four-week percent change
in HAMD17 scores in Placebo group.
Metabolites Correlation p-value q-value
5-MTPOL 20.40 0.0075 0.49
MEL 20.16 0.29 0.99
5-HT 20.15 0.33 0.99
5-HTP 0.093 0.55 0.99
5-MTPM 0.069 0.66 0.99
TRP 20.044 0.78 0.99
5-HIAA 0.028 0.86 0.99
NA-5-HT 20.021 0.90 0.99
Note: A positive correlation coefficient indicates that higher concentrations of
metabolites are associated with a better four-week response of depression
status.
Abbreviations: 5-MTPM = 5-methoxytryptamine. For the remaining metabolites,
see Table 1.
doi:10.1371/journal.pone.0068283.t007
Table 8. Correlations of pre-treatment levels of ratios of
metabolites within the tryptophan pathway to four week
percent change in HAMD17 scores in Placebo group.
Ratios Correlation p-value
5-HTP/TRP 0.14 0.38
5-HT/TRP 20.15 0.34
NA-5-HT/TRP 20.044 0.78
5-HIAA/TRP 0.091 0.56
5-MTPOL/TRP 20.3 0.048
MEL/TRP 20.1 0.52
5MTPM/TRP 0.039 0.81
5-HT/5-HTP 20.12 0.45
NA-5-HT/5-HTP 20.15 0.32
5-HIAA/5-HTP 20.072 0.65
5-MTPOL/5-HTP 20.28 0.071
MEL/5-HTP 20.22 0.16
5MTPM/5-HTP 20.04 0.80
NA-5-HT/5-HT 0.081 0.61
5-HIAA/5-HT 0.14 0.37
5-MTPOL/5-HT 20.15 0.32
MEL/5-HT 20.059 0.71
5MTPM/5-HT 0.29 0.062
MEL/NA-5-HT 20.16 0.31
MEL/5MTPM 20.18 0.25
NA-5-HT/5MTPM 20.00076 1.00
5-HIAA/5MTPM 0.057 0.72
5-MTPOL/5MTPM 20.29 0.059
Note: A positive correlation coefficient indicates that responders favor higher
ratios.
Abbreviations: 5-MTPM = 5-methoxytryptamine. For the remaining metabolites,
see Table 1.
doi:10.1371/journal.pone.0068283.t008
Table 9. Change in tryptophan pathway ratios in responders
and nonresponders to placebo.
Responder Nonresponder
Ratio Estimate p-value Estimate p-value
KYN/TRP 20.0085 0.67 20.0027 0.89
KYN/5-HTP 0.043 0.39 20.0051 0.93
KYN/5-HT 20.0063 0.89 0.05 0.075
KYN/NA-5-HT 20.0023 0.95 0.018 0.48
KYN/MEL 20.37 0.038 0.19 0.18
KYN/5-MTPOL 20.099 0.079 0.038 0.28
3-OHKY/TRP 0.011 0.74 0.034 0.27
3-OHKY/5-HTP 0.063 0.22 0.032 0.60
3-OHKY/5-HT 0.014 0.79 0.086 0.015
3-OHKY/NA-5-HT 0.018 0.66 0.055 0.056
3-OHKY/MEL 20.35 0.046 0.22 0.11
3-OHKY/5-MTPOL 20.079 0.16 0.074 0.075
Abbreviations: For the metabolites, see Table 1.
doi:10.1371/journal.pone.0068283.t009
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non-responders to sertraline. The ratios in KYN/MEL and 3-
OHKY/MEL were significantly decreased only in the responders.
Taken together, these observations suggest that more favorable
outcome of the sertraline treatment is associated with the effect on
methoxyindole branch of tryptophan pathway, compared to the
effect on the kynurenine branch. Increased ratios in KYN/5-HT
and 3-OHKY/5-HT might seem to contradict this suggestion.
However, levels of KYN and its metabolites, and of methox-
yindoles in plasma reflect their respective levels in cerebrospinal
fluid [37], while plasma 5-HT levels do not. Therefore, it’s more
likely that the observed effects on KYN and methoxyindoles are
more related to the central effect of sertraline. Several of the
changes observed in the sertraline group were also evident in the
group receiving placebo, including pre- to post-treatment increases
in 4-HPLA, tocopherols, METH, TYR and HGA. The magnitude
of these changes was not large and may reflect the progression of
the disease or other factors such as changes in behavioral patterns
(e.g., changes in diet) related to the recovery process. Perhaps the
most important similarities emerged when examining changes in
metabolites in responders and non-responders. Similarly to
sertraline, significant increases in 5-MTPOL and MEL were
found only among responders to placebo. This suggests that
response to sertraline and to placebo share some common
mechanisms probably reflecting change in depression unrelated
to specific treatment that involves methoxyindole branch of the
tryptophan pathway. Responders to placebo did not show
reduction in 5-MTPM suggesting that decrease in this metabolite
be a specific effect that is related to sertraline.
Several studies implicated methoxyindole and kynurenine
branches of tryptophan metabolism in the pathogenesis of
depression and in mechanisms of action SSRIs [38–40]. The results
of the present study suggest for the first time that a potential
mechanism underlying good or poor response to treatment could be
related to the differential effects of the drug on these two branches of
the pathway, i.e., engagement of the methoxyindole branch is
associated with response to the therapy with SSRI. Analysis of four
week change revealed that a greater increase in 5-MTPOL and
MEL levels was associated with a greater reduction in HAMD17
scores during the four week treatment period. The link between
disorganization of circadian rhythms and depression has been well
documented, and changed MEL secretion has been observed in the
patients with MDD [41–43]. Melatonin receptors agonists were
proposed as potential novel antidepressants. Efficacy of agomela-
tine, an agonist of MT1 and MT2 melatonin receptors, in clinical
trials was found to be similar to that of SSRIs [44–46]. In this
respect it is interesting that in animal studies chronic administration
of fluoxetine induced several-fold increase in brain arylalkylamine
N-acetyltransferase (AANAT) mRNA [47]. AANAT synthesizes
NA-5-HT from 5-HT, and NA-5-HT is the first and critical step in
MEL synthesis. It was found that NA-5-HT could be not just a MEL
precursor but could exert an antidepressant effect by itself, and this
effect of NA-5-HT is related to a circadian cycle [48]. These
findings, along with the results of our study suggest that
heterogeneity within MDD could in part be related to differential
regulation of the methoxyindole branch and could underlie the
differences in response to therapy with sertraline. The potential role
of AANAT and production of melatonin and other methoxyindoles
and their contribution to recovery from a depressed state should be
explored in greater details.
Although melatonin has been extensively studied as a product of
the pineal gland other methoxyindoles are less well studied; both
central and peripheral effects have been described for these
compounds. 5-MTPOL is regulated during the circadian cycle
similarly to melatonin [49],[50] and is involved in regulation of the
hormonal axis [51]. 5-MTPM, a tryptamine derivative, closely
related to 5-HT and MEL, occurs naturally in the body in low
levels and could be synthesized via the deacetylation of melatonin
in the pineal gland and contribute to production of 5-MTPOL,
and is also involved in the regulation of the hormonal axis
[52],[53]. These observations along with the findings of this study
suggest that methoxyindoles could be involved in pathogenesis of
depression and its treatment outcomes. Circadian rhythm
dysfunction is linked to depressive states, [54–57], and SSRIs
modify circadian locomotor activity rhythms [58]. The relation-
ship between perturbations in the circadian cycle, depression, sleep
pattern changes, production of methoxyindoles and regulation of
the hormonal axis remains to be further explored.
Limitations of this study include a relatively small sample size
and relatively short duration of treatment. Longer treatment
periods should help to determine which changes occur earlier,
better define the relation between response and biochemical
changes, and better discern the ability of early changes to predict
latter outcomes. In future studies we will focus on effects of SSRIs
and placebo on other pathways, this should extend findings
reported and explain variability that exists between responders
and non-responders in more details. Additionally correlations
between peripheral and central metabolic changes induced by
drug and placebo should be investigated. This can lead to the
identification of peripheral biomarkers that are disease related and
that can be more easily measured. Additionally, a potential
limitation of this study is lack of the group of MDD patients
without any treatment. While without such group of subjects the
possibility still exists that response to placebo could not be
distinguished from spontaneous recovery, justification of such
clinical trial design could be problematic due to the ethical
concerns; future studies are necessary to address this question.
In conclusion, our results suggest a potential role for methox-
yindoles in mechanisms of recovery from depressed state, a finding
that needs to be followed upon where samples should be collected
during the day and night hours to define how the circadian cycle,
production of methoxyindoles, changes in sleep patterns and
hormonal axis are modified in responders and non-responders to
SSRIs and to placebo.
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